Document:

EX-10.28

 Exhibit 10.28 

AMENDMENT NO. 1 to OFFICER EMPLOYMENT AGREEMENT 

This Amendment No. 1 to Officer Employment Agreement (“Amendment”) is made April 10, 2019 (“Amendment Effective
Date”) and is by and between Caribou Biosciences, Inc., a Delaware corporation, having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (the “Company”), and Rachel E.
Haurwitz, Ph.D. (the “Officer”). 
 WHEREAS, the Company and the Officer have entered into an Officer Employment Agreement, having
an Effective Date of June 30, 2017 (the “Agreement”); and 
 WHEREAS, the Company and the Officer desire to update the
Agreement as set forth herein and in accordance with Section 15 of the Agreement; 
 NOW, THEREFORE, in consideration of the mutual
covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Officer agree as follows: 

 

	1.	 The Agreement is amended to delete Section 7 in its entirety and replace it with the following
Section 7: 

 7. Relief. The Officer agrees that it would be difficult to measure any damages
caused to the Company which might result from any breach by the Officer of this Agreement, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Officer agrees that if the Officer breaches, or
proposes to breach, this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to
the Company. In addition, in the event the Officer breaches the Confidential Information and Invention Assignment Agreement, effective as of April 10, 2019, by and between the Company and the Officer (“CIIA”), during a period when he
or she is receiving severance payments pursuant to Section 4(b) or (c), the Company shall have the right to suspend or terminate such severance payments. Such suspension or termination shall not limit the Company’s other options with
respect to relief for such breach and shall not relieve the Officer of his or her duties under this Agreement. 
  

	2.	 The Agreement is amended to delete Section 9 in its entirety and replace it with the following
Section 9: 

 9. Integration. This Agreement constitutes the entire agreement between the parties with
respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, with the sole exception of the CIIA and the Indemnification Agreement, dated September 11, 2014, both by and between
the Company and the Officer. If there are any conflicts between the terms and conditions of the CIIA and this Agreement, the terms and conditions of this Agreement shall govern. 

 IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 to Officer
Employment Agreement as of the Amendment Effective Date. 
  

									
	Caribou Biosciences, Inc.	 		 	Rachel E. Haurwitz, Ph.D.
					
	By:	 	 /s/ Barbara G. McClung, J.D.
	 		 	By:	 	 /s/ Rachel E. Haurwitz, Ph.D.

		 	Barbara G. McClung J.D.	 		 		 	
		 	Chief Legal Officer and Corporate Secretary	 		 		 	

  
 - 2 -EX-10.29

 Exhibit 10.29 

[Caribou Biosciences, Inc. Letterhead] 

Confidential 
 February 19, 2021 

Rachel Haurwitz 
 2512 Sherborne Drive 

Belmont, CA 94002 
 Dear Rachel: 

Effective January 1, 2021, your base salary will be $495,000 with a target bonus of 45%. You will receive a retroactive payment for January 1 to
February 15, 2021 in your next paycheck (February 26, 2021). 
 I am pleased to announce that the Caribou Board of Directors has approved a bonus
based on the Company’s achievements in 2020. You will receive a one-time payment of $202,500.00, less applicable withholding taxes, on February 26, 2021. 

In spite of the many challenges that 2020 thrust upon the Company, our communities, and our families, the herd impressively managed to accomplish many of the
Company’s 2020 corporate goals: 
  

	 	•	 	 filing the IND for CB-010 and initiating the ANTLER Phase 1 trial,

  

	 	•	 	 nominating a third pipeline program, 

 

	 	•	 	 establishing a robust and reproducible process for iNK differentiation, 

 

	 	•	 	 ~50% insertion in primary T cells with a long non-viral DNA template
using Cas12a chRDNAs, and 

  

	 	•	 	 implementing Type I editing in iPSC lines. 

Other goals that we did not complete by the end of 2020 are well underway or already completed including manufacturing GLP material for CB-011, closing a strategic partnership, and closing the Series C. The other members of the Board and I are grateful to you for your hard work and your support of these multiple key efforts. Caribou has the exciting
and challenging opportunity to transform our cutting-edge technologies into therapies with best-in-class potential. Only through the continued collective efforts of the
herd will we achieve our ambitious 2021 goals. 
 Please let Cindy know if you want to contribute to your 401(k) account from this bonus payment. Nothing in
this letter shall be construed as a guarantee of employment, your employment remains at-will, and the Company reserves the right to change your title, reporting structure, and/or compensation at any time. As a
reminder, this letter contains Caribou Confidential Information. 
 Best regards, 
  

	
	 /s/ Barbara G. McClung

	
	Barbara G. McClung
	Chief Legal Officer and Corporate SecretaryEX-10.31

 Exhibit 10.31 

CONFIDENTIAL 
 OFFICER
EMPLOYMENT AGREEMENT 
 This Officer Employment Agreement (“Agreement”) is made as June 30, 2017 (“Effective
Date”), and is by and between Caribou Biosciences, Inc., a Delaware corporation, having an address at 2929 7th Street, Suite 105, Berkeley, CA 94710 (the “Company”), and Steven B.
Kanner, Ph.D. (the “Officer”). 
 WHEREAS, the Company desires to continue to employ the Officer and the Officer desires to
continue to be employed by the Company on the new terms and conditions contained herein. 
 NOW, THEREFORE, in consideration of the mutual
covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 

1. Employment.  
 a. Term.
The term of this Agreement shall commence on the Effective Date and continue until terminated in accordance with the provisions hereof (the “Term”). 

b. Position and Duties. During the Term, the Officer shall serve as the Chief Scientific Officer of the Company, and shall have
supervision and control over and responsibility for the day-to-day business and affairs of the Company as may from time to time be prescribed by the Company’s
President and Chief Executive Officer of the Company, provided that such duties are consistent with the Officer’s position or other positions that he or she may hold from time to time. The Officer shall devote substantially all of his or her
full working time and efforts to the business of the Company. Notwithstanding the foregoing, the Officer may serve on other boards of directors, with the approval of the Board, or sit on the governing boards of, or hold leadership positions related
to community, charitable, academic, and religious activities as long as such services and activities are disclosed to the Board and do not materially interfere with the Officer’s performance of his or her duties to the Company as provided in
this Agreement. 
 2. Compensation and Related Matters. 

a. Base Salary. During the Term, the Officer’s initial annual base salary shall be $290,000.00. The Officer’s base salary
shall be reviewed from time to time by the Company’s Board of Directors (“Board”) or the Compensation Committee of the Board. The base salary in effect at any given time is referred to herein as “Base Salary.” The Base
Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices. 
 b. Incentive Compensation.
During the Term, the Officer shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Officer’s initial target annual incentive compensation shall be 30% of his or
her Base Salary. Except as otherwise provided herein, to earn incentive compensation, the Officer must be employed by the Company on the day such incentive compensation is paid. 

c. Company Benefits. The Officer shall be entitled to all benefits received by employees of the Company in accordance with the
Company’s policies and plans. 
 3. Termination. During the Term, the Officer’s employment hereunder may be terminated
without any breach of this Agreement under the following circumstances: 
 a. Termination by the Company for Cause. The Company may
terminate the Officer’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean: (i) conduct by the Officer constituting a material act of misconduct in connection with the performance of his or her
duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary, and de minimis use of Company property for personal purposes; (ii) the
commission by the Officer of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or any conduct by the Officer that would reasonably be expected to result in material injury or reputational harm to the Company or any
of its subsidiaries and affiliates if he or she were retained in his or her position; (iii) continued non-performance by the Officer of his or 

 CONFIDENTIAL 

 

 
her duties hereunder (other than by reason of the Officer’s physical or mental illness, incapacity or disability) that has continued for more than 30 days following written notice of such non-performance from the Board; (iv) a material violation by the Officer of the Company’s written policies; or (v) failure to cooperate with a bona fide internal investigation or an investigation by
regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to
fail to cooperate or to produce documents or other materials in connection with such investigation. 
 b. Termination by the Company
Without Cause. The Company may terminate the Officer’s employment hereunder at any time without Cause upon written notice of such termination (“Notice of Termination”). Any termination by the Company of the Officer’s
employment under this Agreement which does not constitute a termination for Cause under Section 3(a) and does not result from the death or disability of the Officer under Section 3(d) or (e), respectively, shall be deemed a termination
without Cause. 
 c. Termination by the Officer. The Officer may terminate his or her employment hereunder at any time for any
reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Officer has complied with the “Good Reason Process” (hereinafter defined) following the occurrence of any of the
following events: (i) a material diminution in the Officer’s responsibilities, authority or duties; (ii) a decrease of more than 10% of the Officer’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all officers of the Company; (iii) a change by the Company in the Company location at which the
Officer performs his or her duties to a location that is more than 50 miles (driving distance) from the original location; or (iv) the material breach of this Agreement by the Company. “Good Reason Process” shall mean that
(i) the Officer reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Officer notifies the Company in writing of the first occurrence of the Good Reason condition within 30 days of the first
occurrence of such condition; (iii) the Officer cooperates in good faith with the Company’s efforts, for a period of 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such
efforts, the Good Reason condition continues to exist; and (v) the Officer terminates his or her employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good
Reason shall be deemed not to have occurred. 
 d. Death. The Officer’s employment hereunder shall terminate upon his or her
death. 
 e. Disability. The Company may terminate the Officer’s employment if he or she is disabled and unable to perform the
essential functions of the Officer’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any
12-month period and the Company shall provide a Notice of Termination at that time. If any question shall arise as to whether during any period the Officer is disabled so as to be unable to perform the
essential functions of the Officer’s then existing position or positions with or without reasonable accommodation, the Officer may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a
physician selected by the Company to whom the Officer or the Officer’s guardian has no reasonable objection as to whether the Officer is so disabled or how long such disability is expected to continue, and such certification shall for the
purposes of this Agreement be conclusive of the issue. The Officer shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Officer shall fail to submit such
certification, the Company’s determination of such issue shall be binding on the Officer. Nothing in this Section 3(b) shall be construed to waive the Officer’s rights, if any, under existing federal and state law including, without
limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601, et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101, et seq. 

f. Notice of Termination. Except for termination as specified in Section 3(d), any termination of the Officer’s employment by
the Company or any such termination by the Officer shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a written notice which shall indicate
the specific termination provision in this Agreement relied upon. 
 g. Date of Termination. “Date of Termination” shall
mean: (i) if the Officer’s employment is terminated by the Company for Cause under Section 3(a) or without Cause under Section 3(b) or on account of disability under Section 3(e), the date on which Notice of Termination is
given; (ii) if the Officer’s employment is terminated by the Officer under Section 3(c) without Good Reason, 30 days after the date on which a Notice of 

  
 - 2 - 

 CONFIDENTIAL 

 

 
Termination is given; (iii) if the Officer’s employment is terminated by the Officer under Section 3(c) with Good Reason, the date on which a Notice of Termination is given after
the end of the Cure Period; and (iv) if the Officer’s employment is terminated by his or her death, the date of his or her death. Notwithstanding the foregoing, in the event that the Officer gives a Notice of Termination to the Company
under Section 3(c), the Company may unilaterally and solely at its own discretion accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement; provided, however, that
in no event shall such accelerated Date of Termination be earlier than the date on which the Notice of Termination is delivered to the Company. 
 4.
Compensation Upon Termination. 
 a. Termination Generally. If the Officer’s employment with the Company is
terminated for any reason, the Company shall pay or provide to the Officer (or to his or her authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements in accordance with
Company policy, and unused vacation that accrued through the Date of Termination on or before the time required by law but in no event more than 30 days after the Officer’s Date of Termination; and (ii) any vested benefits the Officer may
have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”).

 b. Termination by the Company Without Cause or by the Officer with Good Reason. During the Term, if the Officer’s employment
is terminated by the Company without Cause as provided in Section 3(b), or the Officer terminates his or her employment for Good Reason as provided in Section 3(c), then the Company shall provide the Officer with the Accrued Benefit and
the compensation and benefits set forth in this Section 4(b), the latter subject to the Officer signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and
entities, confidentiality, return of property, and non-disparagement, in a form and manner satisfactory to the Company (the “Separation Agreement and Release”) and the Separation Agreement and
Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release: (i) the Company shall pay the Officer an amount equal to 9 months of the Officer’s Base Salary (the “Severance
Amount”); (ii) if the Officer (and his or her dependents, if applicable) was participating in the Company’s group health plans immediately prior to the Date of Termination and the Officer elects COBRA health continuation for himself or
herself (and his or her dependents, if applicable), then the Company shall pay for 9 months or the Officer’s COBRA health continuation period, whichever ends earlier, the COBRA health contribution that the Company would have made to provide
health insurance to the Officer (and his or her dependents, if applicable) if the Officer had remained employed by the Company; provided, however, that the Company shall only be required to pay that percentage of dependent health insurance that the
Company would be paying if the Officer had remained employed by the Company; (iii) 100% of the Officer’s then-unvested stock options and restricted stock, if any, shall become immediately vested, and the Officer shall have 12 months from the
Date of Termination in which to exercise his or her stock options (regardless of any language to the contrary in any stock plan then in effect); and (iv) the amounts payable under Sections 4(b)(i) and (ii) shall be paid out in
substantially equal installments in accordance with the Company’s payroll practice over 9 months commencing within 30 days after the date the Separation Agreement and Release becomes fully effective; provided, however, that the initial payment
shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for
purposes of Treasury Regulation Section 1.409A-2(b)(2). 
 c. Change of Control. During
the Term, if within 12 months after a Change in Control as defined herein, the Officer’s employment is terminated by the Company without Cause as provided in Section 3(b) or the Officer terminates his or her employment for Good Reason as
provided in Section 3(c), then, subject to the signing of the Separation Agreement and Release by the Officer and the Separation Agreement and Release becoming fully effective all within the time frame set forth in the Separation Agreement and
Release, the Officer shall receive the benefits set forth in Section 4(b)(i), (ii), and (iii); provided, however, that notwithstanding the language in Section 4(b)(iv), the Severance Amount set forth in Section 4(b)(i) shall be
payable as a lump sum within 5 business days after the Separation Agreement and Release becomes fully effective (for clarity, the COBRA payments set forth in Section 4(b)(ii) shall be paid in accordance with Section 4(b)(iv)). For purposes
of this Section 4(c), “Change in Control” shall mean any of the following: (i) any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Act”)
(other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any 

  
 - 3 - 

 CONFIDENTIAL 

 

 
of its subsidiaries), together with all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Act) of such
person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 50% or more of the combined voting
power of the Company’s then outstanding securities having the right to vote in an election of the Board (“Voting Securities”) (in such case other than as a result of an acquisition of securities directly from the Company); or
(ii) the date a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the
date of the appointment or election; or (iii) the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the
consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than 50% of the voting shares of the Company
issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan)
of all or substantially all of the assets of the Company. Notwithstanding the foregoing, a “Change in Control” shall not be deemed to have occurred for purposes of the foregoing clause solely as the result of an acquisition of securities
by the Company that, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to 50% or more of the combined voting power of all of the then
outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or
similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns 50% or more of the combined voting power of all of the then outstanding Voting Securities, then a “Change
in Control” shall be deemed to have occurred. 
 5. Additional Limitations and Section 409A. 

a. Additional Limitations. Notwithstanding anything to the contrary in this Agreement, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Officer, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with
Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”), and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code,
then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Officer becomes subject to the excise tax imposed by Section 4999 of the Code;
provided that such reduction shall only occur if it would result in the Officer receiving a higher After Tax Amount (as defined below) than the Officer would receive if the Aggregate Payments were not subject to such reduction. In such event, the
Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to
Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and
(4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg.
§1.280G-1, Q&A-24(b) or (c). For purposes of this Section 5(a), the “After Tax Amount” means the amount of the Aggregate Payments less all
federal, state, and local income, excise and employment taxes imposed on the Officer as a result of the Officer’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Officer shall be deemed to pay federal
income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in
each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. The determination as to whether a reduction in the Aggregate Payments shall be made
pursuant to Section 5(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Officer within 15
business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Officer. Any determination by the Accounting Firm shall be binding upon the Company and the Officer. 

b. Section 409A. Notwithstanding anything to the contrary in this Agreement, if at the time of the Officer’s separation from
service within the meaning of Section 409A of the Code, the Company determines that the 

  
 - 4 - 

 CONFIDENTIAL 

 

 
Officer is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Officer becomes entitled to under
this Agreement on account of the Officer’s separation from service would be considered deferred compensation otherwise subject to the 20% additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of
Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) 6 months and one day after the Officer’s separation from service or (B) the
Officer’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid
during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Officer during the time periods set forth in this Agreement. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement
in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for
another benefit. To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that
such payment or benefit is payable upon the Officer’s termination of employment, then such payments or benefits shall be payable only upon the Officer’s “separation from service.” The determination of whether and when a
separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). The parties intend that this Agreement will be administered in
accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder
comply with Section 409A of the Code. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and
regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. The Company makes no representation or warranty and shall have no liability to the Officer or any other person if any provisions
of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section 409A. 

6. Litigation and Regulatory Cooperation. During and after the Term, the Officer shall cooperate fully with the Company in the defense or
prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company that relate to events or occurrences that transpired while the Officer was employed by the Company. The Officer’s
full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.
During and after the Term, the Officer also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or
occurrences that transpired while the Officer was employed by the Company. The Company shall reimburse the Officer for any reasonable out-of-pocket expenses incurred in
connection with the Officer’s performance of obligations pursuant to this Section 6 and, after his or her employment with the Company terminates, the Officer may be entitled for reasonable compensation for his or her time. For the
avoidance of doubt, nothing in this Agreement shall be interpreted or applied to prohibit the Officer from making any good faith report to any governmental agency or other governmental entity concerning any act or omission that the Officer
reasonably believes constitutes a possible violation of federal or state law or making other disclosures that are protected under the anti-retaliation or whistleblower provisions of applicable federal or state law or regulation. 

7. Relief. The Officer agrees that it would be difficult to measure any damages caused to the Company which might result from any breach
by the Officer of this Agreement, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Officer agrees that if the Officer breaches, or proposes to breach, this Agreement, the Company shall be
entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company. In addition, in the event the
Officer breaches the At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement, dated [DATE], by and between the Company and the Officer, during a period when he or she is
receiving severance payments pursuant to Section 4(b) or (c), the Company shall have the right to suspend or terminate such severance payments. Such suspension or termination shall not limit the Company’s other options with respect to
relief for such breach and shall not relieve the Officer of his or her duties under this Agreement. 

  
 - 5 - 

 CONFIDENTIAL 

 

 8. Governing Law and Jurisdiction. This Agreement shall be governed by the laws of the
State of California, and the parties hereby consent to the jurisdiction of the state and federal courts in the State of California. 
 9.
Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, with the sole exception
of the At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement, dated June 30, 2017, and the Indemnification. Agreement, dated June 30, 2017, both by and between
the Company and the Officer. If there are any conflicts between the terms and conditions of the At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement and this Agreement,
the terms and conditions of this Agreement shall govern. 
 10. Successor to the Officer. This Agreement shall inure to the benefit of
and be enforceable by the Officer’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Officer’s death after his or her termination of employment but prior to the completion
by the Company of all payments due him or her under this Agreement, the Company shall continue such payments to the Officer’s beneficiary designated in writing to the Company prior to his or her death (or to his or her estate, if the Officer
fails to make such designation). 
 11. Enforceability. If any portion or provision of this Agreement (including, without limitation,
any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in
circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

12. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Officer’s employment to the extent necessary to effectuate the terms contained herein. 
 13. Waiver. No waiver of any provision
hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not
prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 
 14. Notices. Any
notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage
prepaid, return receipt requested, to the Officer at the last address the Officer has filed in writing with the Company or, in the case of the Company, at the address set forth above to the President and Chief Executive Officer with a copy to
legalnotices@cariboubio.com; provided that if the Officer providing notice is the President and Chief Executive Officer, she is not required to provide notice to herself but instead shall provide written notice to the Chief Legal Officer.

 15. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Officer and by a duly authorized
representative of the Company. 
 16. Successor to Company. The Company shall require any successor (whether direct or indirect, by
purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no
succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement. 

17. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be
taken to be an original; but such counterparts shall together constitute one and the same document. 

  
 - 6 - 

 CONFIDENTIAL 

 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date. 

 

									
	Caribou Biosciences, Inc.	 		 	Steven B. Kanner, Ph.D.
					
	By:	 	 /s/ Rachel E. Haurwitz
	 		 	By:	 	 /s/ Steven B. Kanner

					
	Name:	 	 Rachel E. Haurwitz, Ph.D.
	 		 		 	
					
	Title:	 	 President and CEO
	 		 		 	

  
 - 7 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]